SureTrader
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

USRM RSS Feed
Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: buythebuy
Search This Board:
Last Post: 8/23/2016 10:50:22 PM - Followers: 180 - Board type: Free - Posts Today: 0




A COMMITMENT TO EXCELLENCE

Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 

 


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.

 

.

Management:

Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
 
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.
 

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.
 

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by Amazon.com, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame
 

 

Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director
     

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
    
BHRT - Daily Candlesticks






 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
USRM News: Current Report Filing (8-k) 08/03/2016 04:05:27 PM
USRM News: Quarterly Report (10-q) 08/02/2016 04:05:38 PM
USRM News: Current Report Filing (8-k) 07/28/2016 04:03:53 PM
USRM News: Statement of Ownership (sc 13g) 07/15/2016 06:04:58 AM
USRM News: Statement of Ownership (sc 13g) 06/21/2016 06:04:09 AM
PostSubject
#17044  Sticky Note USRM LATEST PRESS RELEASE! buythebuy 06/25/16 11:39:49 AM
#17383   That's California,and bio heart has subsidiary that's all. akamaii 08/23/16 10:50:22 PM
#17382   "trial lawyers to build a case depending on circumstances" Poor Man - 08/23/16 10:43:18 PM
#17381   Agree. Not bad at all. Garyst 08/23/16 09:54:40 PM
#17380   Quote LOL, "USRM is primed for another run. Hornet Driver 08/23/16 09:33:48 PM
#17379   Prestigious Journal: Unregulated STEM CLINICS: Hornet Driver 08/23/16 09:26:34 PM
#17378   USRM is primed for another run. Low float, buythebuy 08/23/16 08:48:59 PM
#17377   $USRM Performance Report http://www.barchart.com/de $Pistol Pete$ 08/23/16 08:47:50 PM
#17376   Disturbing Revenue Trend Poor Man - 08/23/16 08:27:47 PM
#17375   Yes USRM is a bargain at these levels IMO. buythebuy 08/23/16 04:09:01 PM
#17374   Nice close Go $USRM $Pistol Pete$ 08/23/16 04:08:03 PM
#17373   Quote LOL, "Yep, also nice bids and very Hornet Driver 08/23/16 04:04:56 PM
#17372   Good solid day for USRM! buythebuy 08/23/16 04:01:22 PM
#17371   Yeah, only showing about 255k to 02 now. Garyst 08/23/16 03:02:18 PM
#17370   Yep, also nice bids and very thin to akamaii 08/23/16 02:57:18 PM
#17369   Nice volume today. Garyst 08/23/16 02:53:08 PM
#17368   Gains for who? Cubanwinner 08/23/16 02:04:43 PM
#17367   All buys today bud I'm also Cuban akamaii 08/23/16 02:03:00 PM
#17366   Diluting machine Cubanwinner 08/23/16 01:50:40 PM
#17365   No, all the trades today are from today. Garyst 08/23/16 01:18:24 PM
#17364   Understood. None that I saw posted. Garyst 08/23/16 01:15:24 PM
#17362   Got your proof dog it's locked akamaii 08/23/16 12:24:28 PM
#17361   F?!k was that lol akamaii 08/23/16 12:22:53 PM
#17360   I wouldn't be surprised to see more new buythebuy 08/23/16 12:15:37 PM
#17359   Like the chart here after a attempt run akamaii 08/23/16 12:14:13 PM
#17358   I wouldn't be surprised to see USRM run buythebuy 08/23/16 12:09:58 PM
#17357   Familiar with the t trade just wondering if buythebuy 08/23/16 12:09:13 PM
#17356   What targets are you looking at smart dog akamaii 08/23/16 12:05:52 PM
#17355   So you're saying the one this am was akamaii 08/23/16 12:04:56 PM
#17354   Quote LOL, "Yes and last week when we Hornet Driver 08/23/16 12:04:19 PM
#17353   Being a OTC penny ticker no trading afterhours. Garyst 08/23/16 12:01:48 PM
#17352   Did you happen to notice if USRM had buythebuy 08/23/16 11:59:06 AM
#17351   True. We got our initial huge move last Garyst 08/23/16 11:57:38 AM
#17350   Sure would. Garyst 08/23/16 11:56:46 AM
#17349   Could be we will have to wait and buythebuy 08/23/16 11:50:22 AM
#17348   It's prolly tagging stem and stem is prolly akamaii 08/23/16 11:44:22 AM
#17347   I think it's locked already akamaii 08/23/16 11:42:24 AM
#17346   It would be easy to see the float buythebuy 08/23/16 11:40:59 AM
#17345   That's cool. GO USRM! buythebuy 08/23/16 11:40:14 AM
#17344   Yes and last week when we rose to Garyst 08/23/16 11:34:37 AM
#17343   Co is 30 m from where I live. akamaii 08/23/16 11:29:06 AM
#17342   Yes but more than usual. USRM is starting buythebuy 08/23/16 11:28:07 AM
#17341   Before open yeah but not much 150k or so akamaii 08/23/16 11:27:09 AM
#17340   There was spike in volume at market open. buythebuy 08/23/16 11:20:52 AM
#17339   Had a open order they blew past it akamaii 08/23/16 11:16:38 AM
#17338   That's a pretty good percentage of the float. buythebuy 08/23/16 11:11:35 AM
#17337   Close to a million bidding 013 and up Garyst 08/23/16 11:08:10 AM
#17335   Quote LOL, "Heather Young on Facebook, Patient TBI-001 Hornet Driver 08/23/16 10:39:37 AM
#17334   I hope the volume holds all day. GO USRM! buythebuy 08/23/16 10:39:33 AM
#17333   So far so good this morning. Garyst 08/23/16 10:37:00 AM
#17332   Good volume today for USRM. buythebuy 08/23/16 10:29:25 AM
PostSubject